English
简体中文
Total: £ 56.28
Published Date: 2025-09-18 | Pages: 104 | Tables: 104 | Pharma & Healthcare
The global market for PDE-3 Inhibitors was valued at US$ 656 million in the year 2024 and is projected to reach a revised size of US$ 899 million by 2031, growing at a CAGR of 4.7% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PDE-3 Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
PDE-3 inhibitors are a class of drugs that inhibit phosphodiesterase-3 activity, thereby increasing intracellular cAMP levels in cardiac muscle cells, producing positive inotropic and vasodilatory effects. They are primarily used in the treatment of acute heart failure, cardiogenic shock, and certain peripheral vascular conditions. The upstream supply chain relies on high-purity active pharmaceutical ingredients (APIs) and fine chemical intermediates, largely produced by manufacturers in Europe, the U.S., and India, such as Lonza, Evonik, and Dr. Reddy's. Formulation requires high-quality excipients and strict sterile processing, with common excipients like lactose, hydroxypropyl methylcellulose, and microcrystalline cellulose supplied by global excipient leaders.
Downstream applications are concentrated in hospitals, particularly cardiology departments and intensive care units (ICUs), with end customers including large tertiary hospitals, specialized cardiac centers, and emergency care providers. With the rising global burden of cardiovascular diseases and the growing incidence of acute heart failure in aging populations, demand for PDE-3 inhibitors remains steady. However, their usage is somewhat constrained by potential side effects and competition from more advanced therapeutic alternatives.
In 2024, the global average price of PDE-3 inhibitors is approximately USD 5.7 per unit (with “unit” defined as either one oral tablet or one injection ampoule), and the total sales volume reaches about 115 million units.
North American market for PDE-3 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PDE-3 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PDE-3 Inhibitors include Hikma Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Viatris, Otsuka Pharmaceutical, Sawai Pharmaceutical, Eurofarma, Italfarmaco, Korea United Pharm, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PDE-3 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PDE-3 Inhibitors.
The PDE-3 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PDE-3 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PDE-3 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Hikma Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Viatris
Otsuka Pharmaceutical
Sawai Pharmaceutical
Eurofarma
Italfarmaco
Korea United Pharm
The Menarini Group
Pfizer
Sanofi
Qilu Pharmaceutical
Yabao Pharmaceuticals
Lunan Better Pharmaceutical
Yangtze River Pharmaceuticals
Segment by Type
Amrinone/Inamrinone
Anagrelide
Cilostazol
Dipyridamole
Milrinone
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PDE-3 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PDE-3 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 PDE-3 Inhibitors Market Overview
1.1 Product Definition
1.2 PDE-3 Inhibitors by Type
1.2.1 Global PDE-3 Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Amrinone/Inamrinone
1.2.3 Anagrelide
1.2.4 Cilostazol
1.2.5 Dipyridamole
1.2.6 Milrinone
1.2.7 Others
1.3 PDE-3 Inhibitors by Application
1.3.1 Global PDE-3 Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global PDE-3 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PDE-3 Inhibitors Revenue 2020-2031
1.4.2 Global PDE-3 Inhibitors Sales 2020-2031
1.4.3 Global PDE-3 Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PDE-3 Inhibitors Market Competition by Manufacturers
2.1 Global PDE-3 Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global PDE-3 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PDE-3 Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PDE-3 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PDE-3 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PDE-3 Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of PDE-3 Inhibitors, Date of Enter into This Industry
2.8 Global PDE-3 Inhibitors Market Competitive Situation and Trends
2.8.1 Global PDE-3 Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PDE-3 Inhibitors Players Market Share by Revenue
2.8.3 Global PDE-3 Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PDE-3 Inhibitors Market Scenario by Region
3.1 Global PDE-3 Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PDE-3 Inhibitors Sales by Region: 2020-2031
3.2.1 Global PDE-3 Inhibitors Sales by Region: 2020-2025
3.2.2 Global PDE-3 Inhibitors Sales by Region: 2026-2031
3.3 Global PDE-3 Inhibitors Revenue by Region: 2020-2031
3.3.1 Global PDE-3 Inhibitors Revenue by Region: 2020-2025
3.3.2 Global PDE-3 Inhibitors Revenue by Region: 2026-2031
3.4 North America PDE-3 Inhibitors Market Facts & Figures by Country
3.4.1 North America PDE-3 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PDE-3 Inhibitors Sales by Country (2020-2031)
3.4.3 North America PDE-3 Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe PDE-3 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PDE-3 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PDE-3 Inhibitors Sales by Country (2020-2031)
3.5.3 Europe PDE-3 Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PDE-3 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific PDE-3 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PDE-3 Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific PDE-3 Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PDE-3 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PDE-3 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PDE-3 Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America PDE-3 Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa PDE-3 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PDE-3 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PDE-3 Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa PDE-3 Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PDE-3 Inhibitors Sales by Type (2020-2031)
4.1.1 Global PDE-3 Inhibitors Sales by Type (2020-2025)
4.1.2 Global PDE-3 Inhibitors Sales by Type (2026-2031)
4.1.3 Global PDE-3 Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global PDE-3 Inhibitors Revenue by Type (2020-2031)
4.2.1 Global PDE-3 Inhibitors Revenue by Type (2020-2025)
4.2.2 Global PDE-3 Inhibitors Revenue by Type (2026-2031)
4.2.3 Global PDE-3 Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global PDE-3 Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global PDE-3 Inhibitors Sales by Application (2020-2031)
5.1.1 Global PDE-3 Inhibitors Sales by Application (2020-2025)
5.1.2 Global PDE-3 Inhibitors Sales by Application (2026-2031)
5.1.3 Global PDE-3 Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global PDE-3 Inhibitors Revenue by Application (2020-2031)
5.2.1 Global PDE-3 Inhibitors Revenue by Application (2020-2025)
5.2.2 Global PDE-3 Inhibitors Revenue by Application (2026-2031)
5.2.3 Global PDE-3 Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global PDE-3 Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Hikma Pharmaceuticals
6.1.1 Hikma Pharmaceuticals Company Information
6.1.2 Hikma Pharmaceuticals Description and Business Overview
6.1.3 Hikma Pharmaceuticals PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Hikma Pharmaceuticals PDE-3 Inhibitors Product Portfolio
6.1.5 Hikma Pharmaceuticals Recent Developments/Updates
6.2 Takeda Pharmaceutical
6.2.1 Takeda Pharmaceutical Company Information
6.2.2 Takeda Pharmaceutical Description and Business Overview
6.2.3 Takeda Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Takeda Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.2.5 Takeda Pharmaceutical Recent Developments/Updates
6.3 Teva Pharmaceutical
6.3.1 Teva Pharmaceutical Company Information
6.3.2 Teva Pharmaceutical Description and Business Overview
6.3.3 Teva Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.3.5 Teva Pharmaceutical Recent Developments/Updates
6.4 Torrent Pharmaceuticals
6.4.1 Torrent Pharmaceuticals Company Information
6.4.2 Torrent Pharmaceuticals Description and Business Overview
6.4.3 Torrent Pharmaceuticals PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Torrent Pharmaceuticals PDE-3 Inhibitors Product Portfolio
6.4.5 Torrent Pharmaceuticals Recent Developments/Updates
6.5 Viatris
6.5.1 Viatris Company Information
6.5.2 Viatris Description and Business Overview
6.5.3 Viatris PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Viatris PDE-3 Inhibitors Product Portfolio
6.5.5 Viatris Recent Developments/Updates
6.6 Otsuka Pharmaceutical
6.6.1 Otsuka Pharmaceutical Company Information
6.6.2 Otsuka Pharmaceutical Description and Business Overview
6.6.3 Otsuka Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Otsuka Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.6.5 Otsuka Pharmaceutical Recent Developments/Updates
6.7 Sawai Pharmaceutical
6.7.1 Sawai Pharmaceutical Company Information
6.7.2 Sawai Pharmaceutical Description and Business Overview
6.7.3 Sawai Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Sawai Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.7.5 Sawai Pharmaceutical Recent Developments/Updates
6.8 Eurofarma
6.8.1 Eurofarma Company Information
6.8.2 Eurofarma Description and Business Overview
6.8.3 Eurofarma PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Eurofarma PDE-3 Inhibitors Product Portfolio
6.8.5 Eurofarma Recent Developments/Updates
6.9 Italfarmaco
6.9.1 Italfarmaco Company Information
6.9.2 Italfarmaco Description and Business Overview
6.9.3 Italfarmaco PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Italfarmaco PDE-3 Inhibitors Product Portfolio
6.9.5 Italfarmaco Recent Developments/Updates
6.10 Korea United Pharm
6.10.1 Korea United Pharm Company Information
6.10.2 Korea United Pharm Description and Business Overview
6.10.3 Korea United Pharm PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Korea United Pharm PDE-3 Inhibitors Product Portfolio
6.10.5 Korea United Pharm Recent Developments/Updates
6.11 The Menarini Group
6.11.1 The Menarini Group Company Information
6.11.2 The Menarini Group Description and Business Overview
6.11.3 The Menarini Group PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 The Menarini Group PDE-3 Inhibitors Product Portfolio
6.11.5 The Menarini Group Recent Developments/Updates
6.12 Pfizer
6.12.1 Pfizer Company Information
6.12.2 Pfizer Description and Business Overview
6.12.3 Pfizer PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Pfizer PDE-3 Inhibitors Product Portfolio
6.12.5 Pfizer Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Company Information
6.13.2 Sanofi Description and Business Overview
6.13.3 Sanofi PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Sanofi PDE-3 Inhibitors Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 Qilu Pharmaceutical
6.14.1 Qilu Pharmaceutical Company Information
6.14.2 Qilu Pharmaceutical Description and Business Overview
6.14.3 Qilu Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Qilu Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.14.5 Qilu Pharmaceutical Recent Developments/Updates
6.15 Yabao Pharmaceuticals
6.15.1 Yabao Pharmaceuticals Company Information
6.15.2 Yabao Pharmaceuticals Description and Business Overview
6.15.3 Yabao Pharmaceuticals PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Yabao Pharmaceuticals PDE-3 Inhibitors Product Portfolio
6.15.5 Yabao Pharmaceuticals Recent Developments/Updates
6.16 Lunan Better Pharmaceutical
6.16.1 Lunan Better Pharmaceutical Company Information
6.16.2 Lunan Better Pharmaceutical Description and Business Overview
6.16.3 Lunan Better Pharmaceutical PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Lunan Better Pharmaceutical PDE-3 Inhibitors Product Portfolio
6.16.5 Lunan Better Pharmaceutical Recent Developments/Updates
6.17 Yangtze River Pharmaceuticals
6.17.1 Yangtze River Pharmaceuticals Company Information
6.17.2 Yangtze River Pharmaceuticals Description and Business Overview
6.17.3 Yangtze River Pharmaceuticals PDE-3 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Yangtze River Pharmaceuticals PDE-3 Inhibitors Product Portfolio
6.17.5 Yangtze River Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PDE-3 Inhibitors Industry Chain Analysis
7.2 PDE-3 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PDE-3 Inhibitors Production Mode & Process Analysis
7.4 PDE-3 Inhibitors Sales and Marketing
7.4.1 PDE-3 Inhibitors Sales Channels
7.4.2 PDE-3 Inhibitors Distributors
7.5 PDE-3 Inhibitors Customer Analysis
8 PDE-3 Inhibitors Market Dynamics
8.1 PDE-3 Inhibitors Industry Trends
8.2 PDE-3 Inhibitors Market Drivers
8.3 PDE-3 Inhibitors Market Challenges
8.4 PDE-3 Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global PDE-3 Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global PDE-3 Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global PDE-3 Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global PDE-3 Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global PDE-3 Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global PDE-3 Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global PDE-3 Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market PDE-3 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of PDE-3 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of PDE-3 Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PDE-3 Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of PDE-3 Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PDE-3 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PDE-3 Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PDE-3 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global PDE-3 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 18. Global PDE-3 Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global PDE-3 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 20. Global PDE-3 Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global PDE-3 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global PDE-3 Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global PDE-3 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global PDE-3 Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America PDE-3 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America PDE-3 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 27. North America PDE-3 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 28. North America PDE-3 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America PDE-3 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe PDE-3 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe PDE-3 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 32. Europe PDE-3 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 33. Europe PDE-3 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe PDE-3 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific PDE-3 Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific PDE-3 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific PDE-3 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific PDE-3 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific PDE-3 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America PDE-3 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America PDE-3 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 42. Latin America PDE-3 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 43. Latin America PDE-3 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America PDE-3 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa PDE-3 Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa PDE-3 Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa PDE-3 Inhibitors Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa PDE-3 Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa PDE-3 Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global PDE-3 Inhibitors Sales (K Units) by Type (2020-2025)
Table 51. Global PDE-3 Inhibitors Sales (K Units) by Type (2026-2031)
Table 52. Global PDE-3 Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global PDE-3 Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global PDE-3 Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global PDE-3 Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global PDE-3 Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global PDE-3 Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global PDE-3 Inhibitors Price (US$/Unit) by Type (2020-2025)
Table 59. Global PDE-3 Inhibitors Price (US$/Unit) by Type (2026-2031)
Table 60. Global PDE-3 Inhibitors Sales (K Units) by Application (2020-2025)
Table 61. Global PDE-3 Inhibitors Sales (K Units) by Application (2026-2031)
Table 62. Global PDE-3 Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global PDE-3 Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global PDE-3 Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global PDE-3 Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global PDE-3 Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global PDE-3 Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global PDE-3 Inhibitors Price (US$/Unit) by Application (2020-2025)
Table 69. Global PDE-3 Inhibitors Price (US$/Unit) by Application (2026-2031)
Table 70. Hikma Pharmaceuticals Company Information
Table 71. Hikma Pharmaceuticals Description and Business Overview
Table 72. Hikma Pharmaceuticals PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Hikma Pharmaceuticals PDE-3 Inhibitors Product
Table 74. Hikma Pharmaceuticals Recent Developments/Updates
Table 75. Takeda Pharmaceutical Company Information
Table 76. Takeda Pharmaceutical Description and Business Overview
Table 77. Takeda Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Takeda Pharmaceutical PDE-3 Inhibitors Product
Table 79. Takeda Pharmaceutical Recent Developments/Updates
Table 80. Teva Pharmaceutical Company Information
Table 81. Teva Pharmaceutical Description and Business Overview
Table 82. Teva Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Teva Pharmaceutical PDE-3 Inhibitors Product
Table 84. Teva Pharmaceutical Recent Developments/Updates
Table 85. Torrent Pharmaceuticals Company Information
Table 86. Torrent Pharmaceuticals Description and Business Overview
Table 87. Torrent Pharmaceuticals PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Torrent Pharmaceuticals PDE-3 Inhibitors Product
Table 89. Torrent Pharmaceuticals Recent Developments/Updates
Table 90. Viatris Company Information
Table 91. Viatris Description and Business Overview
Table 92. Viatris PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Viatris PDE-3 Inhibitors Product
Table 94. Viatris Recent Developments/Updates
Table 95. Otsuka Pharmaceutical Company Information
Table 96. Otsuka Pharmaceutical Description and Business Overview
Table 97. Otsuka Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Otsuka Pharmaceutical PDE-3 Inhibitors Product
Table 99. Otsuka Pharmaceutical Recent Developments/Updates
Table 100. Sawai Pharmaceutical Company Information
Table 101. Sawai Pharmaceutical Description and Business Overview
Table 102. Sawai Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Sawai Pharmaceutical PDE-3 Inhibitors Product
Table 104. Sawai Pharmaceutical Recent Developments/Updates
Table 105. Eurofarma Company Information
Table 106. Eurofarma Description and Business Overview
Table 107. Eurofarma PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Eurofarma PDE-3 Inhibitors Product
Table 109. Eurofarma Recent Developments/Updates
Table 110. Italfarmaco Company Information
Table 111. Italfarmaco Description and Business Overview
Table 112. Italfarmaco PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Italfarmaco PDE-3 Inhibitors Product
Table 114. Italfarmaco Recent Developments/Updates
Table 115. Korea United Pharm Company Information
Table 116. Korea United Pharm Description and Business Overview
Table 117. Korea United Pharm PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Korea United Pharm PDE-3 Inhibitors Product
Table 119. Korea United Pharm Recent Developments/Updates
Table 120. The Menarini Group Company Information
Table 121. The Menarini Group Description and Business Overview
Table 122. The Menarini Group PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. The Menarini Group PDE-3 Inhibitors Product
Table 124. The Menarini Group Recent Developments/Updates
Table 125. Pfizer Company Information
Table 126. Pfizer Description and Business Overview
Table 127. Pfizer PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Pfizer PDE-3 Inhibitors Product
Table 129. Pfizer Recent Developments/Updates
Table 130. Sanofi Company Information
Table 131. Sanofi Description and Business Overview
Table 132. Sanofi PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Sanofi PDE-3 Inhibitors Product
Table 134. Sanofi Recent Developments/Updates
Table 135. Qilu Pharmaceutical Company Information
Table 136. Qilu Pharmaceutical Description and Business Overview
Table 137. Qilu Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Qilu Pharmaceutical PDE-3 Inhibitors Product
Table 139. Qilu Pharmaceutical Recent Developments/Updates
Table 140. Yabao Pharmaceuticals Company Information
Table 141. Yabao Pharmaceuticals Description and Business Overview
Table 142. Yabao Pharmaceuticals PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Yabao Pharmaceuticals PDE-3 Inhibitors Product
Table 144. Yabao Pharmaceuticals Recent Developments/Updates
Table 145. Lunan Better Pharmaceutical Company Information
Table 146. Lunan Better Pharmaceutical Description and Business Overview
Table 147. Lunan Better Pharmaceutical PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Lunan Better Pharmaceutical PDE-3 Inhibitors Product
Table 149. Lunan Better Pharmaceutical Recent Developments/Updates
Table 150. Yangtze River Pharmaceuticals Company Information
Table 151. Yangtze River Pharmaceuticals Description and Business Overview
Table 152. Yangtze River Pharmaceuticals PDE-3 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Yangtze River Pharmaceuticals PDE-3 Inhibitors Product
Table 154. Yangtze River Pharmaceuticals Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. PDE-3 Inhibitors Distributors List
Table 158. PDE-3 Inhibitors Customers List
Table 159. PDE-3 Inhibitors Market Trends
Table 160. PDE-3 Inhibitors Market Drivers
Table 161. PDE-3 Inhibitors Market Challenges
Table 162. PDE-3 Inhibitors Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. Authors List of This Report
List of Figures
Figure 1. Product Picture of PDE-3 Inhibitors
Figure 2. Global PDE-3 Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global PDE-3 Inhibitors Market Share by Type: 2024 & 2031
Figure 4. Amrinone/Inamrinone Product Picture
Figure 5. Anagrelide Product Picture
Figure 6. Cilostazol Product Picture
Figure 7. Dipyridamole Product Picture
Figure 8. Milrinone Product Picture
Figure 9. Others Product Picture
Figure 10. Global PDE-3 Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global PDE-3 Inhibitors Market Share by Application: 2024 & 2031
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Global PDE-3 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global PDE-3 Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 17. Global PDE-3 Inhibitors Sales (2020-2031) & (K Units)
Figure 18. Global PDE-3 Inhibitors Average Price (US$/Unit) & (2020-2031)
Figure 19. PDE-3 Inhibitors Report Years Considered
Figure 20. PDE-3 Inhibitors Sales Share by Manufacturers in 2024
Figure 21. Global PDE-3 Inhibitors Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest PDE-3 Inhibitors Players: Market Share by Revenue in PDE-3 Inhibitors in 2024
Figure 23. PDE-3 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global PDE-3 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America PDE-3 Inhibitors Sales Market Share by Country (2020-2031)
Figure 26. North America PDE-3 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 27. United States PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe PDE-3 Inhibitors Sales Market Share by Country (2020-2031)
Figure 30. Europe PDE-3 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 31. Germany PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific PDE-3 Inhibitors Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific PDE-3 Inhibitors Revenue Market Share by Region (2020-2031)
Figure 38. China PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America PDE-3 Inhibitors Sales Market Share by Country (2020-2031)
Figure 46. Latin America PDE-3 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 47. Mexico PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Colombia PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa PDE-3 Inhibitors Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa PDE-3 Inhibitors Revenue Market Share by Country (2020-2031)
Figure 53. Turkey PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. UAE PDE-3 Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of PDE-3 Inhibitors by Type (2020-2031)
Figure 57. Global Revenue Market Share of PDE-3 Inhibitors by Type (2020-2031)
Figure 58. Global PDE-3 Inhibitors Price (US$/Unit) by Type (2020-2031)
Figure 59. Global Sales Market Share of PDE-3 Inhibitors by Application (2020-2031)
Figure 60. Global Revenue Market Share of PDE-3 Inhibitors by Application (2020-2031)
Figure 61. Global PDE-3 Inhibitors Price (US$/Unit) by Application (2020-2031)
Figure 62. PDE-3 Inhibitors Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
